COMP <GO>
BSEM vs ABBV // GROSS PROFIT MARGIN
BioStem Technologies Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: BSEM 1
— ABBV 9
▲ GROSS PROFIT MARGIN LEADER: BSEM
LAST: $1.29 (-14.57%) • MKT CAP: $24.1M
gross-margins
93.60%
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
gross-margins
70.20%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BSEM VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | BSEM | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | 93.60% | 70.20% | +23.40 | BSEM | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -5.70% | 29.00% | -34.70 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 33.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | 3.47% | — | TIE | /fcf-yield <GO> |
| Operating Margin | -1.50% | 24.60% | -26.10 | ABBV | /operating-margins <GO> |
| Net Profit Margin | -13.90% | 6.90% | -20.80 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | -31.80% | 8.60% | -40.40 | ABBV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.44 | 5.33 | -2.89 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 7/9 | -2.00 | ABBV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 21.9 | 65.1 | -43.16 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.15 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 113.1x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $24.1M | $513.86B | -$513.84B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | BSEM REV | ABBV REV | BSEM GROSS % | ABBV GROSS % | BSEM FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $47.5M | $61.16B | 93.6% | 70.2% | $6.6M | $17.82B |
| FY 2024 | $69.7M | $56.33B | 80.3% | 70.0% | $24.0M | $17.83B |
| FY 2023 | — | $54.32B | — | — | — | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BSEM // BETA —
ABBV // BETA 1.15